In the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Currently Amended) A method of identifying patients with Huntington's disease, or individuals who are at risk of developing Huntington's disease, who will respond to treatment with eicosapentaenoic acid ~~EPA~~(EPA) in any bioavailable form comprising the step of determining the number of CAG repeats in the Huntingtin gene and identifying those subjects with 45 or fewer repeats.

2. (Currently Amended) ~~A~~The method ~~according to~~of claim 1, in which the treatment comprises administration of ~~ethyl-EPA~~eicosapentaenoic acid (ethyl-EPA).

3. (Currently Amended) A method of treating Huntington's disease comprising the steps of identifying patients having 45 or fewer CAG repeats in the gene for huntingtin and administering to those patients eicosapentaenoic acid ~~EPA~~(EPA) in any bioavailable form.

4. (Currently Amended) A method of preventing the development of symptoms in individuals who are at risk of developing Huntington's disease comprising the steps of identifying individuals having 45 or fewer CAG repeats in the gene for huntingtin and administering to those individuals eicosapentaenoic acid ~~EPA~~(EPA) in any bioavailable form.

5. (Currently Amended) ~~A~~The method ~~according to~~of claim 3 ~~or 4~~ in which the eicosapentaenoic acid ~~EPA~~(EPA) administered is in the form of ~~ethyl-EPA~~ethyl-eicosapentaenoic acid (ethyl-EPA).

6. (New) The method of claim 4 in which the eicosapentaenoic acid (EPA) administered is in the form of ethyl-eicosapentaenoic acid (ethyl-EPA).